Cookie Statement

This site uses cookies to store information on your computer. Some are essential to make our site work; others help us improve the user experience. By using the site, you consent to the placement of these cookies. You may at any time change the settings regarding cookies. Read our privacy statement to learn more.

SUPERIOR DIAGNOSTIC YIELD

This exceeded range of estimated rates from all forms of simulated IM (1.1-13.5%).

95% CI included for ICM and one-time monitoring incidence rates.

Range included for repeated monitoring incidence rates.

AF & STROKE: RISK FACTORS15,16

CHADS2 Score: Evaluates ischemic stroke risk in patients with AF

Congestive heart failure

Hypertension

Age

Diabetes

Stroke/TIA/ thromboembolism

SOCIETY RECOMMENDATIONS & GUIDELINES

INSERTABLE CARDIAC MONITORING

EHRA Recommendations17

The European Heart Rhythm Association (EHRA) recommends insertable loop recorders (insertable cardiac monitors) like Reveal LINQ™ ICM for palpitations for the following indications:

Increasing monthly in frequency

Associated with hemodynamic compromise

Other listed examinations prove inconclusive

Non-compliant patients without hemodynamic compromise when a clinically significant arrhythmic cause is likely or must be ruled out

ACC/AHA Ambulatory ECG Guidelines 200018

These guidelines represent some of the current common clinical uses of ambulatory ECG.

For Assessment of Symptoms of Cardiac Arrhythmias

Class

Recommended Use

I

Patients with unexplained syncope, near syncope, or episodic dizziness without obvious cause.

Patients with unexplained recurrent palpitation.

IIb

Patients with episodic shortness of breath, chest pain, or fatigue that is not otherwise explained.

Patients with neurologic events when transient atrial fibrillation or flutter is suspected.

Patients with symptoms such as syncope, near syncope, episodic dizziness, or palpitation in whom a probable cause other than an arrhythmia has been identified but in whom symptoms persist despite treatment of this other cause.

Patients with unexplained syncope, near syncope, or episodic dizziness without obvious cause.

Patients with unexplained recurrent palpitation.

IIb

Patients with episodic shortness of breath, chest pain, or fatigue that is not otherwise explained.

Patients with neurologic events when transient atrial fibrillation or flutter is suspected.

Patients with symptoms such as syncope, near syncope, episodic dizziness, or palpitation in whom a probable cause other than an arrhythmia has been identified but in whom symptoms persist despite treatment of this other cause.

Evidence for Cardiac monitoring

Reveal ICM: Clinical and Cost Effectiveness19

Higher Diagnostic Yield, Lower Cost for Palpitations Diagnosis

Reveal ICM has been shown to be both clinically effective and cost effective when treating palpitations.

Results of the RUP study show:

A 73% diagnostic yield for Reveal ICM, compared to a 21% yield for conventional tests

January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. December 2, 2014;130(23):2071-2104.

Raviele A, Giada F, Bergfeldt L, et al. Management of patients with palpitations: a position paper from the European Heart Rhythm Association. Europace. July 2011;13(7):920-934.

18

ACC/AHA Guidelines for Ambulatory Electrocardiography: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). JACC. 1999.